The value of using COVID-19 antibody tests as a potential approach to prioritize vaccination delivery
The reported results emphasize the value of using immunity tests to prioritize the groups that may benefit the most from the limited vaccines, especially in developing countries with scarce resources where those with COVID-19 IgG antibodies should have less priority for the COVID-19 vaccine. The present results indicate that up to 40% of the delivered vaccines to HCWs who had COVID-19 antibodies could be prioritized more wisely in future pandemics.
Authors
- Razan Haddad (ORCID: https://orcid.org/0000-0001-5437-6394)
- Daher Al-rabadi
- Karem H. Alzoubi (ORCID: https://orcid.org/0000-0002-2808-5099)
- Omar S. Obeidat (ORCID: https://orcid.org/0000-0003-2847-1309)
- Ibrahim Al‐Faouri (ORCID: https://orcid.org/0000-0001-6840-8828)
- Nasr Alrabadi (ORCID: https://orcid.org/0000-0002-5541-8362)
- Noor Alyassin
- Saif M. Shteiwi
- Haneen Obeidat (ORCID: https://orcid.org/0009-0006-3326-1882)
Institutions
- University of Jordan (JO)
- Jordan University of Science and Technology (JO)
- Jadara University (JO)
- University of Sharjah (AE)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1371/journal.pone.0311881
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jordan University of Science and Technology